A Scottish university is in line for a multi-million-pound windfall after a cancer drug it pioneered was licensed for sale in the United States. Strathclyde University has already earned about £6 million in royalties thanks to the 6S-Leucovorin drug, which is currently only available in Europe. The drug is used in the treatment of colorectal cancers and is also given to patients following chemotherapy. It has now been licensed to Targent Inc and acquired by Spectrum Pharmaceuticals, which aims to distribute it across North America.
The Scotsman